vascuCAP vs Tempus ECG-Low EF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, vascuCAP, specializes in analyzing CT angiograms to quantify plaque composition and assess cardiovascular risk for personalized treatment decisions. In contrast, Tool B, Tempus ECG-Low EF, analyzes 12-lead ECGs to detect signs of low left ventricular ejection fraction, aiding in the identification of patients at risk for heart failure. While both are AI-powered cardiology tools, they utilize different input data and address distinct diagnostic questions within cardiovascular health.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is designed for non-invasive CT angiography analysis to quantify plaque composition and assess cardiovascular risk for optimizing treatment decisions. Tempus ECG-Low EF analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure, providing a binary output to aid clinicians in further evaluation.
vascuCAP requires non-invasive CT angiogram images for its analysis. Tempus ECG-Low EF analyzes resting, non-ambulatory 12-lead ECG recordings.
vascuCAP provides histologically-validated plaque quantification and characterization, including lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, along with 3D visualization and risk stratification for stroke and heart attack. Tempus ECG-Low EF provides a binary output (Low LVEF Detected / Not Detected) to aid in identifying patients at risk of heart failure due to low LVEF.
vascuCAP is primarily intended for Cardiology, Radiology, and Vascular Surgery. Tempus ECG-Low EF is designed for use in Cardiology, Emergency Medicine, and Internal Medicine.
Yes, vascuCAP focuses on risk stratification for stroke and heart attack by analyzing detailed plaque composition. Tempus ECG-Low EF aims to identify patients 40 years or older at risk of heart failure by detecting signs associated with low LVEF.
vascuCAP supports personalized treatment decisions for symptomatic and asymptomatic patients by analyzing vascular imaging. Tempus ECG-Low EF specifically aids in identifying patients 40 years or older at risk of heart failure, including those with conditions like atrial fibrillation, aortic stenosis, cardiomyopathy, myocardial infarction, diabetes, and hypertension.
More Comparisons
Backers
Who funded each tool's parent company.